Does pelacarsen (TQJ230, hepatic apo(a) antisense, 80 mg SC monthly) meet its primary endpoint — superiority over placebo in reducing expanded MACE — in the established-CVD, Lp(a) ≥70 mg/dL primary population of Lp(a)HORIZON?

68% likely to meet · raimo

target Lp(a) particle + LPA (apolipoprotein(a)) · moa GalNAc-conjugated antisense oligonucleotide; hepatic APO(a) mRNA knockdown; ~80% Lp(a) lowering · failure mode biomarker lowered without proportional outcome benefit; lifelong-genetic causal effect fails to translate to 5-yr pharmacologic exposure (low translation fraction tau)

1. premise LPA is a top-tier causal genetic locus for ASCVD: a 10 mg/dL lower genetically-determined Lp(a) associates with ~5.8% lower coronary heart disease risk (genetic log-HR ~= -0.00597 per mg/dL). https://pubmed.ncbi.nlm.nih.gov/29926099/
2. premise Pelacarsen lowers Lp(a) ~80% at trough; time-averaged for titration/adherence ~68% effective. On the >=70 mg/dL-enriched population (median est. ~105 mg/dL) that is ~70 mg/dL absolute reduction. https://www.sciencedirect.com/science/article/pii/S0002870325001012
3. premise Lp(a)HORIZON is event-driven, ending at 993 confirmed primary MACE events (1:1). By Schoenfeld, power = Phi(|lnHR|*15.76 - 1.96): ~88% at HR 0.82, ~73% at HR 0.85, ~59% at HR 0.87 — generously powered. https://www.sciencedirect.com/science/article/pii/S0002870325001012 https://clinicaltrials.gov/study/NCT04023552
4. inference Bridge: predicted HR = exp(absolute_reduction * tau * -0.00597), tau = lifelong-genetic -> 5-yr-pharmacologic translation fraction. The required-reduction literature brackets tau (Burgess conservative ~100 mg/dL per 20% RRR; Lamina optimistic ~50 mg/dL per 20% RRR). https://pubmed.ncbi.nlm.nih.gov/29926099/ https://pubmed.ncbi.nlm.nih.gov/31017618/
5. inference Sensitivity grid (power to hit p<0.05): only weak-translation (tau~0.4) x modest-baseline (~85 mg/dL) misses materially (~59%); the base case (M~105, tau~0.5-0.6) is 80-98% powered. All uncertainty localizes onto tau, never demonstrated for Lp(a) - HORIZON is the first test. https://pubmed.ncbi.nlm.nih.gov/31017618/
6. prediction Pelacarsen meets its primary expanded-MACE endpoint vs placebo in the Lp(a)>=70 population. p(met)=0.68: above coin-flip because the genetic slope is steep and 993 events powers the MR-implied effect generously; capped below ~0.75 by first-in-class translation (tau) risk and the absence of any prior positive Lp(a) outcome trial.

Evidence: https://pubmed.ncbi.nlm.nih.gov/29926099/, https://pubmed.ncbi.nlm.nih.gov/31017618/, https://www.sciencedirect.com/science/article/pii/S0002870325001012, https://clinicaltrials.gov/study/NCT04023552